1 Total size of the pipeline 2001-2012 Citeline annual review 2012 ?? Adverse drug reactions (ADMET) Can Ayurvedic Treatment Help in Integrating with Modern.

Slides:



Advertisements
Similar presentations
SOMA2 – Drug Design Environment. Drug design environment – SOMA2 The SOMA2 project Tekes (National Technology Agency of Finland) DRUG2000 program.
Advertisements

1 Real World Chemistry Virtual discovery for the real world Joe Mernagh 19 May 2005.
Modern Methods in Drug Discovery WS11/12
Analysis of High-Throughput Screening Data C371 Fall 2004.
Case Study: Dopamine D 3 Receptor Anthagonists Chapter 3 – Molecular Modeling 1.
PhysChem Forum, 29 Nov 2006, Newhouse 1 Memories and the future: From experimental to in silico physical chemistry Han van de Waterbeemd AstraZeneca, DMPK.
Modern Tools for Drug Discovery NIMBUS Biotechnology Modern Tools for Drug Discovery
In silico small molecule discovery Sales Target gene Discover hit Hit to lead Optimise lead Clinical Target gene identified with a viable assay High throughput.
Ionization and dissociation of drugs-1
PharmaMiner: Geometric Mining of Pharmacophores 1.
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Lipinski’s rule of five
Establishing a Successful Virtual Screening Process Stephen Pickett Roche Discovery Welwyn.
Bioinformatics IV Quantitative Structure-Activity Relationships (QSAR) and Comparative Molecular Field Analysis (CoMFA) Martin Ott.
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
Chemoinformatics in Molecular Docking and Drug Discovery.
Chemoinformatics in Drug Design
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Validation of Model of Cytochrome P450 2D6: An in Silico Tool for Predicting Metabolism and Inhibition Carol A. Kemp, Jack U. Flanagan, Annamaria J. van.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Structure-based Drug Design
Chapter 9: Making new antibiotics. Model organisms are used to speed drug discovery A model organism is a non-human species that is extensively studied.
Drug discovery and development
Lecture 7: Computer aided drug design: Statistical approach. Lecture 7: Computer aided drug design: Statistical approach. Chen Yu Zong Department of Computational.
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
1 The Discovery Informatics Framework Pat Rougeau President and CEO MDL Information Systems, Inc. Delivering the Integration Promise American Chemical.
Functional groups / Pharmacological Activity
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
FKPPL workshop May 2012 BUI The Quang Prof. Vincent Breton Prof. Doman Kim Prof. NGUYEN Hong Quang Prof. PHAM Quoc Long Grid enabled in silico drug discovery.
Introduction to Pharmacoinformatics
Identification of New Inhibitors of Plasmodium falciparum Enoyl- ACP Reductase Symposium on: Advances in Parasitology “Education and Research in Parasitology.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
CS 790 – Bioinformatics Introduction and overview.
Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.
DE NOVO DESIGN OF A THYMIDYLATE KINASE INHIBITOR.
INFSO-RI Enabling Grids for E-sciencE V. Breton, 30/08/05, seminar at SERONO Grid added value to fight malaria Vincent Breton EGEE.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Page 1 SCAI Dr. Marc Zimmermann Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Grid-enabled drug discovery.
Ligand-based drug discovery No a priori knowledge of the receptor What information can we get from a few active compounds.
CZ3253: Computer Aided Drug design Lecture 1: Drugs and Drug Development Part I Prof. Chen Yu Zong Tel:
SimBioSys Inc.© Slide #1 Enrichment and cross-validation studies of the eHiTS high throughput screening software package.
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
Altman et al. JACS 2008, Presented By Swati Jain.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Pharmacophores Chapter 13 Part 2.
DuPont Pharmaceuticals Company Utilization of Spotfire™ in Quality Assessment & Analysis of Screening Data Thomas D.Y. Chung, Ph.D. Sr. Director, Leads.
PharmaMiner: Geometric Mining of Pharmacophores 1.
Lipophilicity & Permeability 김연수. Chapter 5. Lipophilicity.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
Use of Machine Learning in Chemoinformatics
Discovery of Therapeutics to Improve Quality of Life Ram Samudrala University of Washington.
Part 2. Physicochemical Properties 1.Rules ( 양혜란 ) 2.Liphophilicity ( 백아름 ) 3.pKa ( 박숙진 ) 4.Solubility ( 전종수, 최영재 ) 5.Permeability ( 김소연, 강경태 )
Docking and Virtual Screening Using the BMI cluster
Molecular Modeling in Drug Discovery: an Overview
Physiochemical properties of drugs Some background to the Sirius T3.
Julia Salas CS379a Aim of the Study To determine distinguishing features of orally administered drugs –Physical and structural features probed.
Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.
Structural Bioinformatics Elodie Laine Master BIM-BMC Semester 3, Genomics of Microorganisms, UMR 7238, CNRS-UPMC e-documents:
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
Semantic Web - caBIG Abstract: 21st century biomedical research is driven by massive amounts of data: automated technologies generate hundreds of.
Chemistry 301 Q1 September 14, 2017: Agenda
SEMINAR 1. Title : Discovery of Protein-Protein Interaction Modulators Using Affinity-Based High-Throughput Screening 2. Speaker : Hyun-Suk Lim (포항공대 (POSTECH))
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
DATA MINING FOR SMALL MOLECULE ALLOSTERIC INHIBITORS
Molecular Docking Profacgen. The interactions between proteins and other molecules play important roles in various biological processes, including gene.
Virtual Screening.
Insight into the Pharmaceutical Industry
Cheminformatics Basics
Patrick: An Introduction to Medicinal Chemistry 6e
Presentation transcript:

1 Total size of the pipeline Citeline annual review 2012 ?? Adverse drug reactions (ADMET) Can Ayurvedic Treatment Help in Integrating with Modern Medicine?

NCI, Specs, IBScreen Databases ( Compounds) Compounds (CH 3 ) 3 N, Lipinski’s rule based screening 117 Compounds Pharmacophore based screening, Fit value ≥ 4 In vitro HTS compounds (ChemDiv, Tripose, ChemBridge) AChE activity < 0.35µM 8 compounds 75 Compounds 9 Compounds Docking based screening, GFS > 52 Blood Brain Barrier, Bioavailability & Toxicity based screening 2 Lead Compounds In vitro screening Flow chart showing different sequential virtual screening techniques 2 Finland Collaboration

3 In Vitro Analysis (Finland collaboration)  AChE Enzyme Assay based on Ellman’s Reagent reaction.  Data set consisted of 8 highly potent compounds (IC 50 < 0.35 µM) obtained from high-throughput in vitro screening consisting of 56,000 compounds for AChE inhibitory activity.  Compounds were taken from 3 Key Databases: ChemDiv Inc (San Diego, US), ChemBridge Corporation (San Diego, US) Tripos (US). Selection of Compounds for Pharmacophore Identification I (0.019 μM) II (0.069 μM) IV (0.204 μM) III (0.152 μM) VI (0.236 μM) V (0.229 μM) VII (0.315 μM) VIII (0.332 μM) #Comb. Chem. and High Throughput Screening 2010, 13,

4 Pharmacophore Model for Anti-Cholinesterase Inhibitors D72 Y121 W279 W84 F330 F288 F331 Y334 CD1 CD1 (IC 50 =0.019 μM) Active binding site residues of AChE enzyme in complex with CD1 molecule

5 Virtually screened Lead Compounds (Specs1 and Specs2) Interaction with AChE Enzyme IC 50 =3.279 μM IC 50 =5.986 μM

6 Compound Structure (Vendor ID)SourceGFS in AChE enzyme (kJ/mol) IC 50 (μM) for AChE inhibition IC 50 (μM) for BChE inhibition (ChemDiv (CD1), (ID= C ) High throughput in vitro screening (ChemDiv (CD2), (ID= E ) (Specs (Specs1), (ID=AF-399/ ) Virtual screening followed by in vitro validation Less inhibition Less inhibition (Specs (Specs2), (ID= AF-399/ ) Structure of the 4 lead compounds along with the AChE and BChE enzyme inhibition, and its GOLD fitness score

CompoundToxicity ab CNS b logS b % H_ O_Abs c AlogP c logD b logBB b PSA CD1 Skin sensitisation CD2None Specs1None Specs2None ADMET parameters of 4 leads obtained from ChemDiv & Specs database a Toxicity prediction using DEREK software; b Prediction using Schördinger software; c Prediction using Discovery studio (DS2.1) ADME module software; CNS= Predicted central nervous system activity on a -2 (inactive) to +2 (active) scale; LogS= Predicted aqueous solubility, log S on a –6.5 to 0.5; % H_O_Abs = Percent Human Oral Absorption; AlogP= Log of the octanol-water partition coefficient using Ghose and Crippen's method; LogD=The octanol-water partition coefficient calculated taking into account the ionization states of the molecule; LogBB= Predicted brain/blood partition coefficient on a -3 to 1.2 scale; PSA= Van der Waals surface area of polar nitrogen and oxygen atoms. 7

8

9

10 Pain Research

Topics of Interest in Ayur Informatics Ayurvedic Drug Designing Biostatistics Computational Languages Distributed Electronic Medical Records Emergency Communications and Remote Monitoring Medicinal Plant Databases Medicinal Plant Genomics Molecular Modelling Networking Rural Clinics with Major Medical Facilities Pharmacogenomics Pharmacoproteomics Plant Datasets and Databases Remote Analysis of Diagnostic Data Remote Information Services & Decision Support Tools for Patient Care Telemedicine, Telemonitoring, Telediagnostics Use of Digital Radios and Personal Communication Services Visualization Technology for Visualizing the Human Anatomy Wireless Information Networks

BIOACTIVE COMPOUNDS FROM NATURAL SOURCES (Natural Products as Lead Compounds in Drug Discovery) Computational Approaches for the Discovery of Natural Lead Structures Wang, S. Q., Q. S. Du, K. Zhao, A. X. Li, D. Q. Wei, and K. C. Chou Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids 33:129–135. Natural products were often viewed as being “too complex” but then have been recognized as a valuable source of interesting and diverse structures. Natural products show higher molecular weight than synthetic drugs, contain more oxygen atoms, fewer nitrogen atoms, three times more stereo centers, their degree of unsaturation is higher than in synthetic drugs and they incorporate less aromatic rings. Although natural products in general contain more rings than drugs, most of them are non-aromatic and part of single fused ring system.

Bioactive compounds from Natural Sources

The major challenge for in silico techniques is the increased molecular weight and the higher number of saturated bonds resulting in higher molecular flexibility. As a rule of thumb, docking and conformational sampling become slow and inaccurate when a molecule has more than seven rotatable bonds. However, these problems are not irresolvable, but have to be addressed while setting up a virtual screening run using natural products taking into account longer computational time. A too high degree of flexibility may also result in promiscuity, that is, a compound is fitted into a binding site in an implausible way, which stresses the need for visual inspection of virtual hits and selection of the most plausible virtual hits. Another putative practical problem is the higher number of stereo centers whose definitions are often neglected during database construction and therefore the programs have to enumerate all stereoisomers, which unnecessarily increase the (virtual) flexibility.

General workflow for Computer assisted strategy for Natural lead discovery (VS=Virtual screening), (NP= Natural product)

Computational workflow for the identification of the active metabolite/s within a natural (Ayurvedic) preparation.